Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Glatiramer Acetate Shows Positive Impact on Average Relapse Rate and Disease Progression in Multiple Sclerosis For Up to 5 Years: Presented at ECTRIMS By Bruce Sylvester MADRID, SPAIN -- October 1, 2006 -- Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores. The findings were presented here on September 28th at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). "Glatiramer treatment not only has a positive impact on relapse rate and disease progression but we found that the effect increases over time, out to 5 years," said lead presenter Paul Hradilek, MD, neurologist, University Hospital, Ostrova, Czech Republic. "The drug is very effective on both fronts in relapsing-remitting MS patients." The study cohort consisted of 96 women and 12 men diagnosed with relapsing-remitting multiple sclerosis who began glatiramer treatment in 1999. For 95 patients glatiramer was their first disease-modifying drug. Thirteen had been treated previously with interferons. For study entry, participants were required to have at least 2 relapses per year or 3 relapses every 2 years and magnetic resonance imaging finding confirming an MS diagnosis. Average time from diagnosis to initiation of treatment with glatiramer was 6.75 years (1-30). Investigators evaluated relapse rate and Expanded Disability Status Scale (EDSS) change in subgroups treated at least 1, 3 or 5 years. Average relapse rate before treatment was 1.5. After 1 year of glatiramer treatment the rate decreased to 0.68. With glatiramer treatment, it continued to decrease after 3 years to 0.51. In the subgroup treated for at least 5 years the relapse rate was 0.31. A majority of subjects showed stable EDSS scores, with an average change in EDSS of 0.1 point after 5 years. The authors noted that 5 patients discontinued treatment. There were 2 skin allergic reactions leading to discontinuation, but no other major side effects. Eleven patients became pregnant during glatiramer treatment, "which was interrupted the day the subjects knew about their pregnancy," Dr. Hradilek said. There were 3 spontaneous abortions and 8 normal deliveries. The researcher did not observe any foetal abnormalities. Copaxone is approved in much of the world for relapsing-remitting MS. It acts as both immunomodulatory and neuroprotective agent. [Presentation title: Treatment of Relapsing-Remitting Multiple Sclerosis With Glatiramer-Acetate: Our 7-Year Clinical Experience. Abstract P368] E-mail this page to a friend or colleague! To print, use this version